Acadia Pharmaceuticals Inc (ACAD) concluded trading on Thursday at a closing price of $15.48, with 2.94 million shares of worth about $45.55 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -14.95% during that period and on September 26, 2024 the price saw a gain of about 1.04%. Currently the company’s common shares owned by public are about 164.65M shares, out of which, 164.62M shares are available for trading.
Stock saw a price change of -5.72% in past 5 days and over the past one month there was a price change of -1.71%. Year-to-date (YTD), ACAD shares are showing a performance of -50.56% which decreased to -34.49% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $14.55 but also hit the highest price of $32.59 during that period. The average intraday trading volume for Acadia Pharmaceuticals Inc shares is 1.70 million. The stock is currently trading -4.06% below its 20-day simple moving average (SMA20), while that difference is down -7.29% for SMA50 and it goes to -22.06% lower than SMA200.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Acadia Pharmaceuticals Inc (NASDAQ: ACAD) currently have 164.65M outstanding shares and institutions hold larger chunk of about 97.62% of that.
The stock has a current market capitalization of $2.57B and its 3Y-monthly beta is at 0.39. PE ratio of stock for trailing 12 months is 86.72, while it has posted earnings per share of $0.18 in the same period. It has Quick Ratio of 1.95 while making debt-to-equity ratio of 0.11. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ACAD, volatility over the week remained 3.56% while standing at 3.48% over the month.
Stock’s fiscal year EPS is expected to rise by 250.04% while it is estimated to increase by 55.89% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Morgan Stanley on August 07, 2024 offering an Equal-weight rating for the stock and assigned a target price range of between $28 and $20 to it. Coverage by BMO Capital Markets stated Acadia Pharmaceuticals Inc (ACAD) stock as an Outperform in their note to investors on June 27, 2024, suggesting a price target of $31 for the stock. On March 12, 2024, Needham Reiterated their recommendations, while on March 12, 2024, Mizuho Downgrade their ratings for the stock with a price target of $25. Stock get an Outperform rating from Robert W. Baird on January 30, 2024.
